Cochlear Valuation Check As Nucleus Nexa System Reaches US Veterans Through VA Clinics

Simply Wall St.

Jan 22

AdvertisementWhat Cochlear’s VA access milestone could mean for shareholders Cochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605140804"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605140804\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605140804?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-22 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605140804","market":"us","top_or_hot":-1,"title":"Cochlear Valuation Check As Nucleus Nexa System Reaches US Veterans Through VA Clinics","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat Cochlear’s VA access milestone could mean for shareholders Cochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-valuation-check-as-nucleus-nexa-system-reaches-us-v\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear Valuation Check As Nucleus Nexa System Reaches US Veterans Through VA Clinics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear Valuation Check As Nucleus Nexa System Reaches US Veterans Through VA Clinics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-valuation-check-as-nucleus-nexa-system-reaches-us-v><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat Cochlear’s VA access milestone could mean for shareholders Cochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-valuation-check-as-nucleus-nexa-system-reaches-us-v\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6100","symbol_name":"保健护理服务","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-valuation-check-as-nucleus-nexa-system-reaches-us-v","article_id":"2605140804","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-valuation-check-as-nucleus-nexa-system-reaches-us-v","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605140804","pubTimestamp":1769087861,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What Cochlear’s VA access milestone could mean for shareholders\nCochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible US military veterans through VA clinics nationwide, opening an additional access point in a key healthcare channel.\nSee our latest analysis for Cochlear.\nWhile Cochlear’s A$270.22 share price has seen a 3.44% 1 month share price return, the 90 day share price return of 7.24% and 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6100":"保健护理服务","BK7007":"医疗保健设备","NPL.SI":"新加坡阅肤有限公司","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","COH.AU":"COCHLEAR LTD"},"translate_title":"Nucleus Nexa系统通过VA诊所到达美国退伍军人，进行人工耳蜗估价检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NPL.SI":1.5,"DCF":1,"COH.AU":1.5},"content_text":"AdvertisementWhat Cochlear’s VA access milestone could mean for shareholders Cochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible US military veterans through VA clinics nationwide, opening an additional access point in a key healthcare channel. See our latest analysis for Cochlear. While Cochlear’s A$270.22 share price has seen a 3.44% 1 month share price return, the 90 day share price return of 7.24% and 1 year total shareholder return of 12.84% suggest recent momentum has softened compared with its 3 and 5 year total shareholder returns of 36.82% and 43.45%. If this VA milestone has you thinking more broadly about medical exposure in your portfolio, it could be worth scanning healthcare stocks for other healthcare names catching market attention. With Cochlear trading at A$270.22, showing a 1 year total shareholder return decline of 12.84% but solid 3 and 5 year returns, is the recent weakness a reset worth considering, or is the market already pricing in future growth? Price-to-Earnings of 45.4x: Is it justified? Cochlear’s last close at A$270.22 equates to a P/E of 45.4x, which screens as cheaper than peers on this metric but still rich against broader medical equipment benchmarks. The P/E ratio compares the company’s share price to its earnings per share and is a common way investors assess how much they are paying for current profits. For a specialist medical equipment business like Cochlear, a higher P/E often reflects expectations for steady earnings growth and a strong competitive position. According to the statements, Cochlear is described as good value versus its peer average P/E of 59.9x. This suggests the market is applying a lower earnings multiple than to similar companies. At the same time, the P/E of 45.4x is slightly above the estimated fair P/E of 44.9x. This implies the current price is a touch ahead of the level that regression based fair ratio work suggests the market could gravitate toward. Compared with the Global Medical Equipment industry average P/E of 28x, Cochlear’s 45.4x stands out as materially higher. This points to a premium attached to its earnings relative to the sector and hints at stronger expectations embedded in the price than for the typical medical equipment name. Explore the SWS fair ratio for Cochlear Result: Price-to-Earnings of 45.4x (OVERVALUED) However, you also need to weigh risks like a 12.84% 1 year total shareholder return decline, as well as any future shifts in VA funding or reimbursement priorities. Find out about the key risks to this Cochlear narrative. Another take: what the DCF model suggests Our DCF model points in a different direction. At A$270.22, Cochlear is trading above the model’s future cash flow value estimate of A$191.33. On this approach, the shares appear overvalued and this raises the question of how much optimism is already in the price. Look into how the SWS DCF model arrives at its fair value. COH Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cochlear for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 876 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Cochlear Narrative If you see the numbers differently or simply want to test your own assumptions against the data, you can build a personal thesis in just a few minutes with Do it your way. A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Cochlear. Looking for more investment ideas? If Cochlear has sharpened your interest in the sector, do not stop here. The broader market holds plenty of other angles worth sizing up with data at your back.  Spot potential value by scanning these 876 undervalued stocks based on cash flows, where cash flow based pricing helps you quickly see which names might be worth a closer look. Tap into fast moving themes by checking out these 23 AI penny stocks and see which smaller tech names are catching attention around artificial intelligence. Build a watchlist for income by reviewing these 13 dividend stocks with yields > 3% and focus on companies offering yields above 3% that may complement your growth holdings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}